Lawrence Otto Klein Sells 2,452 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) CEO Lawrence Klein sold 2,452 shares of the stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $95.71, for a total transaction of $234,680.92. Following the transaction, the chief executive officer directly owned 923,128 shares of the company’s stock, valued at $88,352,580.88. This trade represents a 0.26% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Lawrence Otto Klein also recently made the following trade(s):

• On Tuesday, September 1st, Lawrence Klein sold 75,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $91.83, for a total value of $6,887,250.00.

Oruka Therapeutics Stock Down 3.9%

NASDAQ ORKA traded down $3.73 during trading on Tuesday, hitting $92.20. 784,617 shares of the stock traded hands, compared to its average volume of 741,278. The company has a market capitalization of $6.10 billion, a P/E ratio of -45.42 and a beta of -0.34. Oruka Therapeutics, Inc. has a 12-month low of $14.66 and a 12-month high of $115.51. The firm has a 50-day simple moving average of $95.87 and a 200-day simple moving average of $72.78.

Oruka Therapeutics (NASDAQ:ORKA) last posted its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). As a group, research analysts predict that Oruka Therapeutics, Inc. will post -2.42 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. Weiss Ratings upgraded shares of Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. BTIG Research reiterated a “buy” rating and issued a $151.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Piper Sandler reissued an “overweight” rating and set a $180.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, June 2nd. Wedbush reaffirmed an “outperform” rating and issued a $165.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. Finally, Wall Street Zen downgraded Oruka Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, August 16th. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $133.00.

Hedge Funds Weigh In On Oruka Therapeutics

Several hedge funds have recently bought and sold shares of ORKA. Nykredit A S purchased a new stake in shares of Oruka Therapeutics during the second quarter valued at $29,000. Orion Capital Management LLC purchased a new stake in Oruka Therapeutics in the 2nd quarter valued at about $91,000. Natural Investments LLC bought a new position in Oruka Therapeutics in the 2nd quarter worth about $202,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Oruka Therapeutics during the fourth quarter worth approximately $67,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Oruka Therapeutics during the second quarter valued at approximately $211,000. Institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc (NASDAQ:ORKA) is a clinical-stage biotechnology company developing long-acting monoclonal antibody therapies for immune-mediated diseases. The company’s research is focused on creating medicines that may allow less frequent dosing than existing biologic treatments.

Oruka’s initial development programs are aimed at inflammatory conditions, including psoriasis. Its pipeline includes engineered antibody candidates designed to target important immune pathways, including interleukin-23 and interleukin-17.